Table 1 Clinicopathological characteristics of patients according to mRNA expression level of CXCL16: TCGA cohort dataset.

Age at diagnosis (yrs)

47.1 ± 15.8

47.4 ± 15.8

46.8 ± 15.9

0.692

Sex, male, n(%)

132 (26.8)

62 (25.2)

70 (28.5)

0.416

Histological type, n(%)

Classical

349 (70.9)

148 (60.2)

201 (81.7)

<0.001

Follicular variant

99 (20.1)

88 (35.8)

11 (4.5)

Tall-cell variant

35 (7.1)

5 (2.0)

30 (12.2)

Other variant

9 (1.8)

5 (2.0)

4 (1.6)

BRAF^V600E, n(%)

234 (47.4)

77 (31.2)

157 (63.6)

<0.001

Tumor Size (cm)

2.8 ± 1.6

2.8 ± 1.6

2.8 ± 1.7

0.815

Multifocality, n(%)

220/482 (45.6)

118/241 (49.0)

102/241 (42.3)

0.143

Extrathyroidal extension, n(%)

149/476 (31.3)

54/236 (22.9)

95/240 (39.6)

<0.001

Lymph node metastasis

222/445 (49.9)

78/210 (37.1)

144/235 (61.3)

<0.001

Distant metastasis, n(%)

8/265 (3.0)

5/121 (4.1)

3/144 (2.1)

0.475

TNM staging, n(%)

<0.001

I-II

331/490 (67.6)

183/244 (75.0)

148/246 (60.2)

III-IV

159/490 (32.4)

61/244 (25.0)

98/246 (39.8)

ATA risk, n(%)

<0.001

Low

171/453 (37.7)

115/227 (50.7)

56/226 (24.8)

Intermediate

258/453 (57.0)

100/227 (44.1)

158/226 (69.9)

High

24/453 (5.3)

12/227 (5.3)

12/226 (5.3)

Recurrence, n(%)

27/454 (5.9)

11/227 (4.8)

16/227 (7.0)

0.321

All-cause mortality, n(%)

14/490 (2.9)

7/244 (2.9)

7/246 (2.8)

0.988